Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy.

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy.

Item
http://www.wikidata.org/entity/Q50219574
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.Profile of mirabegron in the treatment of overactive bladder: place in therapy.Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II studIs mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
P2860

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy.

Item
http://www.wikidata.org/entity/Q50219574
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@en
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@nl
type
label
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@en
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@nl
prefLabel
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@en
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Mirabegron as Add-On Treatment ...... se to Solifenacin Monotherapy.
@en
P2093
P304
P31
P356
10.1016/J.JURO.2016.03.174
P407
P433
P478
P50
P577
P698